ATRC

SEC source: 0001323885-24-000036 · wk-form4_1709675153.xml · nonDerivative · entry 1

Wirick Angela L · CIK 0001819885 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,609

F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant.

SEC source: 0001323885-24-000032 · wk-form4_1709675029.xml · nonDerivative · entry 3

Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,784

F3 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award.

SEC source: 0001323885-24-000032 · wk-form4_1709675029.xml · nonDerivative · entry 2

Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,640

F2 · price: The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met.

SEC source: 0001323885-24-000032 · wk-form4_1709675029.xml · nonDerivative · entry 1

Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,312

F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant.

SEC source: 0001323885-24-000037 · wk-form4_1709675173.xml · nonDerivative · entry 3

CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 657,532

F3 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award.

SEC source: 0001323885-24-000037 · wk-form4_1709675173.xml · nonDerivative · entry 2

CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 705,356

F2 · price: The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met.

SEC source: 0001323885-24-000037 · wk-form4_1709675173.xml · nonDerivative · entry 1

CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 636,214

F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant.

SEC source: 0001323885-24-000038 · wk-form4_1709675209.xml · nonDerivative · entry 2

Yount Deborah Lee · CIK 0001926195 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,219

F2 · price: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award.

SEC source: 0001323885-24-000038 · wk-form4_1709675209.xml · nonDerivative · entry 1

Yount Deborah Lee · CIK 0001926195 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,275

F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant.

SEC source: 0001323885-24-000034 · wk-form4_1709675075.xml · nonDerivative · entry 3

Seith Douglas J · CIK 0001565823 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 153,520

F3 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award.

SEC source: 0001323885-24-000034 · wk-form4_1709675075.xml · nonDerivative · entry 2

Seith Douglas J · CIK 0001565823 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 168,116

F2 · price: The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met.

SEC source: 0001323885-24-000034 · wk-form4_1709675075.xml · nonDerivative · entry 1

Seith Douglas J · CIK 0001565823 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,911

F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant.

SEC source: 0001323885-24-000031 · wk-form4_1709674990.xml · nonDerivative · entry 3

Privitera Salvatore · CIK 0001336063 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,290

F3 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award.

SEC source: 0001323885-24-000031 · wk-form4_1709674990.xml · nonDerivative · entry 2

Privitera Salvatore · CIK 0001336063 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,644

F2 · price: The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met.

SEC source: 0001323885-24-000031 · wk-form4_1709674990.xml · nonDerivative · entry 1

Privitera Salvatore · CIK 0001336063 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,511

F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant.

SEC source: 0001323885-24-000022 · wk-form4_1709042411.xml · derivative · entry 2

WHITE ROBERT S. · CIK 0001571208 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Non-qualified Stock Option (right to buy) · 10,000 shares

Expires 2024-05-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: These options were granted on May 14, 2014. These options vest and are exercisable as to 25% of the shares one year from the date of grant and the remaining 75% thereafter vests and are exercisable in equal monthly installments on the same day of the month over the following three years.

SEC source: 0001323885-24-000022 · wk-form4_1709042411.xml · nonDerivative · entry 1

WHITE ROBERT S. · CIK 0001571208 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,985

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001323885-24-000008 · wk-form4_1704721757.xml · nonDerivative · entry 1

Nachman Shlomo · CIK 0002006261 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,322

F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest 33% annually over three years from the date of grant.

SEC source: 0001323885-24-000002 · wk-form4_1704201666.xml · nonDerivative · entry 1

Yount Deborah Lee · CIK 0001926195 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,981

F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended December 31, 2023.

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on December 29, 2023, which is the last trading day of the applicable offering period. The closing price on December 29, 2023 was $35.69.

SEC source: 0001323885-23-000115 · wk-form4_1701266428.xml · nonDerivative · entry 1

CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 585,360

F1 · price: No consideration was received in connection with this charitable gift.

SEC source: 0001323885-23-000112 · wk-form4_1699015194.xml · nonDerivative · entry 1

Dahlquist Karl S. · CIK 0001861996 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,789

F1 · shares: These shares were sold pursuant to a 10b5-1 trading plan adopted on February 24, 2023.

SEC source: 0001323885-23-000103 · wk-form4_1691500899.xml · nonDerivative · entry 1

Wirick Angela L · CIK 0001819885 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,601

F1 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award.

SEC source: 0001323885-23-000101 · wk-form4_1691500781.xml · nonDerivative · entry 1

CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 595,360

F1 · price: No consideration was received in connection with this gift to the reporting person's parents.

SEC source: 0001323885-23-000099 · wk-form4_1690547968.xml · nonDerivative · entry 1

Dahlquist Karl S. · CIK 0001861996 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,037

F1 · shares: These shares were sold pursuant to a 10b5-1 trading plan adopted on February 24, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $56.75 to $57.50 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001323885-23-000081 · wk-form4_1688386579.xml · nonDerivative · entry 1

Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,310

F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2023.

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 3, 2023, which is the first trading day of the applicable offering period. The closing price on January 3, 2023 was $44.84.

SEC source: 0001323885-23-000079 · wk-form4_1688386461.xml · nonDerivative · entry 1

Dahlquist Karl S. · CIK 0001861996 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,454

F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2023.

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 3, 2023, which is the first trading day of the applicable offering period. The closing price on January 3, 2023 was $44.84.

SEC source: 0001323885-23-000083 · wk-form4_1688386678.xml · nonDerivative · entry 1

Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,018

F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2023.

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 3, 2023, which is the first trading day of the applicable offering period. The closing price on January 3, 2023 was $44.84.

SEC source: 0001323885-23-000077 · wk-form4_1688386321.xml · nonDerivative · entry 1

CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 596,610

F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2023.

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 3, 2023, which is the first trading day of the applicable offering period. The closing price on January 3, 2023 was $44.84.

SEC source: 0001323885-23-000089 · wk-form4_1688386948.xml · nonDerivative · entry 1

Yount Deborah Lee · CIK 0001926195 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,883

F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2023.

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 3, 2023, which is the first trading day of the applicable offering period. The closing price on January 3, 2023 was $44.84.

SEC source: 0001323885-23-000085 · wk-form4_1688386782.xml · nonDerivative · entry 1

Privitera Salvatore · CIK 0001336063 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,217

F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2023.

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 3, 2023, which is the first trading day of the applicable offering period. The closing price on January 3, 2023 was $44.84.

SEC source: 0001323885-23-000087 · wk-form4_1688386874.xml · nonDerivative · entry 1

Seith Douglas J · CIK 0001565823 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,012

F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2023.

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 3, 2023, which is the first trading day of the applicable offering period. The closing price on January 3, 2023 was $44.84.

SEC source: 0001323885-23-000075 · wk-form4_1686574751.xml · nonDerivative · entry 1

Prange Karen · CIK 0001566083 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,140

SEC source: 0001323885-23-000073 · wk-form4_1686141814.xml · nonDerivative · entry 1

Dahlquist Karl S. · CIK 0001861996 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,897

F1 · shares: These shares were sold pursuant to a 10b5-1 trading plan adopted on February 24, 2023.

SEC source: 0001323885-24-000112 · wk-form4_1726663825.xml · nonDerivative · entry 1

Yount Deborah Lee · CIK 0001926195 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,337

F1 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award.

SEC source: 0001323885-23-000071 · wk-form4_1685625157.xml · nonDerivative · entry 1

CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 596,053

F1 · price: No consideration was received in connection with this gift to the reporting person's parents.

SEC source: 0001323885-23-000069 · wk-form4_1685477104.xml · nonDerivative · entry 1

Yuen Maggie · CIK 0001796057 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,682

F1 · price: This transaction was executed in multiple trades at prices ranging from $46.86 to $47.27 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001323885-23-000061 · wk-form4_1685132316.xml · nonDerivative · entry 1

Telman Deborah H · CIK 0001860008 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,995

F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

SEC source: 0001323885-23-000059 · wk-form4_1685132069.xml · nonDerivative · entry 1

JOHNSON B KRISTINE · CIK 0001231984 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,621

F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

SEC source: 0001323885-23-000063 · wk-form4_1685132537.xml · nonDerivative · entry 1

WEHRWEIN SVEN · CIK 0001205069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,185

F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

SEC source: 0001323885-23-000067 · wk-form4_1685132919.xml · nonDerivative · entry 1

WHITE ROBERT S. · CIK 0001571208 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,985

F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

SEC source: 0001323885-23-000065 · wk-form4_1685132734.xml · nonDerivative · entry 1

Prange Karen · CIK 0001566083 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,853

F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

SEC source: 0001323885-23-000057 · wk-form4_1685131876.xml · nonDerivative · entry 1

GROVES REGINA E · CIK 0001653877 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,978

F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

SEC source: 0001323885-23-000055 · wk-form4_1685131546.xml · nonDerivative · entry 1

Yuen Maggie · CIK 0001796057 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,995

F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

SEC source: 0001323885-23-000049 · wf-form4_168314416777718.xml · nonDerivative · entry 1

Dahlquist Karl S. · CIK 0001861996 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,319

F1 · shares: These shares were sold pursuant to a 10b5-1 trading plan adopted on February 24, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $44.31 to $45.45 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001323885-23-000035 · wf-form4_167891440770815.xml · derivative · entry 3

Collar Mark A · CIK 0001426353 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Non-qualified Stock Option (right to buy) · 10,000 shares

Expires 2023-05-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: These options were granted on May 23, 2013. These options vest and are exercisable as to 25% of the shares one year from the date of grant and the remaining 75% thereafter vests and are exercisable in equal monthly installments on the same day of the month over the following three years.

SEC source: 0001323885-23-000035 · wf-form4_167891440770815.xml · nonDerivative · entry 1

Collar Mark A · CIK 0001426353 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,871

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001323885-23-000026 · wf-form4_167788145290873.xml · nonDerivative · entry 3

Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,753

F3 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award.

SEC source: 0001323885-23-000026 · wf-form4_167788145290873.xml · nonDerivative · entry 2

Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,546

F2 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant.

SEC source: 0001323885-23-000026 · wf-form4_167788145290873.xml · nonDerivative · entry 1

Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,442

F1 · price: The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The award had both a Company performance goal and a service period requirement, which were both met.

SEC source: 0001323885-23-000031 · wf-form4_167788176034477.xml · nonDerivative · entry 3

Dahlquist Karl S. · CIK 0001861996 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,736

F3 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award.